meclizine (antivert) Report issue

Small molecule Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem repoDB

Active Ingredient History

NOW
  • Now
Meclizine, a piperazine-derivative H1-receptor antagonist similar to buclizine, cyclizine, and hydroxyzine, is used as an antivertigo/antiemetic agent. Meclizine is used in the management of nausea, vomiting, and dizziness associated with motion sickness and vertigo in diseases affecting the vestibular apparatus. Along with its actions as an antagonist at H1-receptors, meclizine also possesses anticholinergic, central nervous system depressant, and local anesthetic effects. Meclizine depresses labyrinth excitability and vestibular stimulation and may affect the medullary chemoreceptor trigger zone. It is sold under the brand names Bonine, Bonamine, Antivert, Postafen, Sea Legs, and Dramamine II.   NCATS

Chemistry

More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Oral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$0.0129 - $4.1420
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

ancoloxin | antivert | meclizine | meclizine hcl | meclizine hydrochloride | meclozine | meclozine dihydrochloride | meclozine hydrochloride | nevidoxine | sea-legs | traveleeze

Organizations (44)

Research & Development (11)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (33)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (10)

Approved Indications (5)


 

Motion Sickness (approved 2012)

Nausea

Postoperative Nausea and Vomiting

Vertigo (approved 2012)

Vomiting

Experimental Indications - Clinical Trial Phases 1-4 (8)


 

Carcinoma, Hepatocellular (Phase 1)

Healthy Volunteers (Phase 1)

Meclizine (Phase 4)

Motion Sickness (Phase 4)

Pharmacology (Phase 4)

Smoking Cessation (Phase 2)

Vertigo (Phase 3)

Vomiting (Phase 1/Phase 2)

Overview

  • Highest Phase: Phase 4
  • # of Trials: 9
  • # of Trial Organizations: 11

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue